Skip to main content

Curtis Rosebraugh, Bruce Stillman

The US Food and Drug Administration announced the appointment last week of Curtis Rosebraugh as the new director of the Office of Drug Evaluation II. Prior to joining FDA in 2000 as a medical officer in the Division of Pulmonary and Allergy Drugs Products, Rosebraugh was an assistant professor of internal medicine at the University of Kansas-Wichita and later an assistant professor of internal medicine and internal medicine clerkship director at the University of Texas Medical Branch-Galveston. From 2003 to 2005, he served as the deputy director of the Office of Nonprescription Products and was acting director of the Division of Nonprescription Clinical Evaluation in the same office. In 2005, Rosebraugh became deputy director of the Office of Drug Evaluation II and became acting director of the office in September 2007.

Cold Spring Harbor Laboratory President Bruce Stillman has been elected to the American Academy of Arts and Sciences. Stillman has been director of the CSHL Cancer Center since 1994 and he has been president since 2003.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.